GlassScriptPhysician profile
Richard S Isaacson
NPI 1124056932
$126,802.67
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $13K · 2021: $81K · 2022: $20K · 2023: $18.75 · 2024: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $369 · Food and Beverage: $18.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $368.76 |
| Food and Beverage | $18.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $62,265.90 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $27,000.00 | 2021-2022 | |
| Novo Nordisk INC | $12,200.60 | 2021-2022 | |
| Eisai INC. | $8,045.08 | 2019 | |
| Eli Lilly and Company | $6,433.58 | 2021-2022 | |
| Roche Products Limited | $4,320.00 | 2020-2021 | |
| Genentech, INC. | $3,000.00 | 2020 | |
| Avanir Pharmaceuticals, INC. | $1,710.00 | 2021 | |
| F. Hoffmann-La Roche Ag | $1,440.00 | 2021 | |
| Lilly USA, LLC | $387.51 | 2023-2024 | Amyvid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Isaacson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.